Discovery of a cAMP Deaminase That Quenches Cyclic AMP-Dependent Regulation

Alissa M. Goble,†‡∥ Youjun Feng,‡∥∥ Frank M. Raushel, † and John E. Cronan*‡§

†Department of Chemistry, Texas A&M University, P.O. Box 30012, College Station, Texas 77843-3012, United States
‡Departments of Microbiology and ∥∥Biochemistry, University of Illinois, Urbana, Illinois 60801, United States

Supporting Information

ABSTRACT: An enzyme of unknown function within the amidohydrolase superfamily was discovered to catalyze the hydrolysis of the universal second messenger, cyclic-3′,5′-adenosine monophosphate (cAMP). The enzyme, which we have named CadD, is encoded by the human pathogenic bacterium Leptospira interrogans. Although CadD is annotated as an adenosine deaminase, the protein specifically deaminates cAMP to cyclic-3′,5′-inosine monophosphate (cIMP) with a $k_{cat}/K_m$ of $2.7 \pm 0.4 \times 10^7$ M$^{-1}$ s$^{-1}$ and has no activity on adenosine, adenine, or 5′-adenosine monophosphate (AMP). This is the first identification of a deaminase specific for cAMP. Expression of CadD in Escherichia coli mimics the loss of adenylyl cyclase in that it blocks growth on carbon sources that require the cAMP−CRP transcriptional activator complex for expression of the cognate genes. The cIMP reaction product cannot replace cAMP as the ligand for CRP binding to DNA in vitro and cIMP is a very poor competitor of cAMP activation of CRP for DNA binding. Transcriptional analyses indicate that CadD expression represses expression of several cAMP−CRP dependent genes. CadD adds a new activity to the cAMP metabolic network and may be a useful tool in intracellular study of cAMP-dependent processes.

The amidohydrolase (AHS) enzyme superfamily is a well-characterized group of enzymes first identified by Holm and Sander based on the similarities in the three-dimensional structures of phosphotriesterase, adenosine deaminase, and urease.1 The proteins of the AHS family fold into a distorted (β/α)$_2$-barrel with conserved metal binding residues at the C-terminal ends of β-strands 1, 4, 5, 6, and 8. These enzymes have either mononuclear or binuclear metal centers that activate a hydrolytic water for nucleophilic attack and are involved in the metabolism of amino acids, sugars, nucleic acids, and organophosphorus esters.2 NCBI has divided the AHS into 24 clusters of orthologous groups (COGs) and annotated all bacterial proteins in COG1816 as enzymes that catalyze the deamination of adenosine. The structure and mechanism of action of adenosine deaminases from several organisms have been studied, and the sequence similarity network3 for COG1816 is given in Figure 1. Enzymes experimentally verified as adenosine deaminases are found in Group 5, which contains the Escherichia coli K-12 adenosine deaminase (locus tag: b1623). Additional adenosine deaminases are found in Groups 1, 2, 6, and 8. The essential residues for adenosine deaminase activity4 include an HxHxD motif following β-strand 1, an aspartate following β-strand 3, a glycine following β-strand 4, an HxExE motif following β-strand 5, a histidine following β-strand 6, and a pair of aspartates following β-strand 8.2 Additional functions found in COG1816 include adenosine deaminase and cytokinin deaminase in Group 3. Despite an overall amino acid sequence identity of ∼30% to E. coli adenosine deaminase, the proteins of Group 18 cannot deaminate adenosine. We have identified a protein of Group 18 of COG1816 that specifically deaminates the signaling molecule cAMP to cyclic-3′,5′-inosine monophosphate (cIMP) and lacks activity on adenosine. We have named this enzyme CadD for cyclic adenylyl deaminase.

The universal signaling molecule cAMP is found in all three domains of life, where it plays key roles as a secondary messenger that transmits signals to regulate physiological processes such as sugar and lipid metabolism, cardiac function, and cell growth and differentiation.5,6 The action of cAMP is mediated by binding to a variety of cAMP receptor proteins. These receptor proteins are divided into four main classes: cyclic nucleotide-dependent kinases, cyclic nucleotide-gated ion channels, guanine nucleotide exchange factors, and bacterial cAMP-dependent transcription factors (CRP).7 In the case of CRP proteins, cAMP binding results in a large well-understood allosteric transition that allows binding to specific DNA sequences.6–8 The deamination product of cAMP, cIMP, has been reported as a compound released into the growth medium by cultures of Corynebacterium musitepticum and Microbacterium sp. 205,8 and a component of mammalian tissue culture cells,11 although in each of these systems the means of cIMP production are unknown. Deamination of cAMP by a broad specificity fungal adenosine deaminase12 and in toad bladder extracts13 has been reported. This work describes the discovery and in vivo function of a cAMP deaminase from the human pathogen, Leptospira interrogans,14 a bacterium transmitted by
Figure 1. Sequence similarity network created using Cytoscape (www.cytoscape.org) of COG1816 from the amidohydrolase superfamily. Each node in the network represents a single sequence, and each edge (depicted as lines) represents the pairwise connection between two sequences at a BLAST E-value of better than $1 \times 10^{-70}$. Lengths of edges are not significant, except for tightly clustered groups, which are more closely related than sequences with only a few connections. Groups 1, 2, 5, 6, and 8 contain the adenosine deaminase enzymes including the *E. coli* adenosine deaminase in Group 5. In Group 3, the sequences depicted in yellow are adenine deaminases whereas the pink sequences represent cytokinin deaminase enzymes. Group 18 (blue) contains CadD, the enzyme studied in this investigation. All proteins of Group 18 are from *Leptospira* strains.

Figure 2. CadD purification, identification, and enzymatic properties. Panels A and B. SDS-polyacrylamide gel analyses of purified CadD protein with detection by either Coomassie Blue staining or by Western blotting with an antihexahistidine antibody. Panel C. Mass spectral identification of the recombinant CadD protein. The peptide fragments matching the database sequence are given in bold and underlined type. Panel D. The CadD reaction. Panel E. CadD deamination of cAMP. The CadD concentration was 5 nM. Panel E. Inhibition of CadD by cPuMP (inset). Inhibition by cPuMP of CadD activity in 25 mM potassium HEPES (pH 7.5). The solid line represents the fit of the data to eq 2.
zoonotic contact that can cause potentially fatal diseases such as renal failure and pulmonary hemorrhage.15

RESULTS AND DISCUSSION

In Vitro Specificity of CadD. CadD was readily expressed at high levels in E. coli and purified to homogeneity. The protein was screened for deaminase activity against a library of compounds (Methods) and showed activity only with cAMP. CadD deaminated cAMP to cIMP (Figure 2) with values of $k_{cat} = 4.6 \pm 4 \text{s}^{-1}$, $K_m = 170 \pm 20 \text{mM}$, and $k_{cat}/K_m = 2.7 \pm 0.4 \times 10^5 \text{M}^{-1} \text{s}^{-1}$. The rate constants for deamination of adenosine, adenine, and AMP were <0.01 s$^{-1}$. Purified CadD contained 0.4 equiv of Zn$^{2+}$ and 0.2 equiv each of Cu$^{2+}$ and Fe$^{3+}$. Purine riboside-3',5'-cyclic monophosphate (cPuMP) was found to be an inhibitor of CadD activity with an inhibition constant of 1.3 $\pm$ 0.5 $\text{mM}$ (Figure 2).

In Vivo Specificity of CadD. High levels of CadD activity were readily obtained upon expression in E. coli, and thus, the protein was not noticeably toxic to growth as expected for an enzyme of narrow specificity. This lack of toxicity allowed us to test if the activity and specificity observed for CadD in vitro extended to an in vivo situation. The cAMP receptor protein (CRP) complex (cAMP−CRP complex) is a global regulator that generally acts as a transcriptional activator in modulating expression of genes involved in various metabolic pathways in E. coli and other bacteria.16−18 DNA binding by CRP requires that the protein first bind cAMP.19,20 When DNA-bound the cAMP−CRP complex interacts with the $\alpha$ subunit of RNA polymerase to allow transcription to proceed.20 The classical role of the cAMP−CRP complex is in determining the "pecking order" of carbon source utilization where glucose has the highest status.17 For example, when E. coli is grown in a mixture of glucose and lactose, the lactose utilization genes (e.g., lacZ encoding $\beta$-galactosidase) are not induced and lactose is not catabolized until the glucose has been exhausted. This is because expression of the lactose operon requires the cAMP−CRP complex to activate transcription even when the lactose repressor is inactive and glucose grown cells have very low cAMP levels.17 Inactivation of the genes encoding either the DNA binding protein, CRP, or the cAMP synthetic enzyme, adenylate cyclase ($\text{crp}$ and $\text{cyaA}$, respectively) results in strains unable to grow with lactose, other sugars such as maltose and arabinose, or low status carbon sources such as fatty acids as sole carbon and energy source.16 The in vitro activity of CadD

Figure 3. CadD expression mimics adenylate cyclase deficiency. Panel A. Growth of E. coli wild type strain MG1655 on various carbon sources in the presence or absence of CadD expression. Glucose does not require cAMP for its utilization whereas cAMP is required for expression of the genes encoding the proteins required to utilize the other sugars. IPTG (0.5 mM) was added for induction of CadD expression. The plates are sectored by plastic walls to prevent cross-feeding. Panels B−E. The cytosolic levels of cAMP in the presence or absence of CadD expression were determined in various strains. For comparison, panel B shows the effects of deleting $\text{cyaA}$, the gene encoding adenylate cyclase. * denotes $p < 0.05$ whereas ** denotes $p < 0.01$. Two E. coli K-12 backgrounds were used. Strain MC4100 was used in much of the early work on cAMP control, but it is unable to grow on lactose or arabinose due to deletion of the lacZYA and araBAD operons, respectively. Hence, the wild type strain MG1655 was used to assay response to these sugars. Strain MC4100 was used for the LacZ fusion studies because its lacZYA deletion eliminates background $\beta$-galactosidase activity. The genomes of both strains have been fully sequenced and their $\text{cyaA}$ and $\text{crp}$ genes and flanking sequences are identical.34
predicted that its expression in a wild type E. coli strain would block growth on lactose, maltose, and arabinose and thereby mimic a cyaA (or crp) mutant strain. Corollaries to this prediction are that intracellular cAMP levels should decline upon CadD expression and that cIMP should be unable to replace cAMP as the ligand required for CRP binding to DNA. All three predictions have been satisfied. Induction of CadD expression in the wild type strain MG1655 blocked growth on lactose, maltose, and arabinose but not on glucose whereas cultures lacking inducer grew well on all four sugars (Figure 3). Moreover, CadD expression resulted in severe decreases in intracellular cAMP levels as expected from the carbon source data (Figure 3). The third prediction was buttressed by an early report that cIMP is a poor replacement for cAMP in allowing CRP to bind DNA. However, the DNA used was a synthetic copolymer that bound the cAMP−CRP complex poorly and thereby resulted in an insensitive assay of poor precision. Other early work was based on an indirect in vitro system in which cIMP was reported to be unable to replace cAMP. However, no details or data were given. To obtain quantitative data using purified CadD and CRP complex binding site, we performed electromobility shift assays of the binding reaction and found that cIMP addition failed to allow CRP to bind DNA even at twice the concentration that sufficed for cAMP (Figure 4). Moreover, addition of purified CadD to the reactions containing both cAMP and CRP blocked formation of the ternary complex with DNA. A final question was whether or not cIMP could effectively compete with the cAMP−CRP complex for DNA binding. Competition was seen only when cIMP was in 500-fold excess over cAMP and a 5000-fold excess of cIMP was needed to abolish DNA binding (Figure 4).

To bridge between the growth phenotypes and DNA binding assays, we assayed the effects on CadD expression on transcription from three CRP-cAMP dependent promoters, those of lacZYA and two fatty acid ß-oxidation pathway genes, fadD and fadH. Expression of the ß-oxidation genes was measured by use of transcriptional fusions to lacZ constructed in the E. coli chromosome. Hence, expression of all three genes could be assayed by ß-galactosidase activity. Transcription from all three promoters was strongly inhibited by expression of CadD (Figure 5). We attempted to reverse the inhibition by addition of exogenous cAMP, which enters E. coli by an unknown and inefficient mechanism. However, this was largely unsuccessful, although a small increase in fadD transcription was seen when CadD was expressed at basal levels suggesting that at induced levels of CadD expression, cAMP deamination was more rapid than cAMP entry (Figure 5). Note that the growth rate and yield of E. coli expressing CadD on glucose as sole carbon source was essentially the same as the strain lacking the amidohydrolase, a finding consistent with the substrate specificity seen in vitro.

Binding of cAMP and cIMP to L. interrogans Cyclic Nucleotide Binding Proteins. Two of the four cloned
putative *L. interrogans* cyclic nucleotide binding proteins produced soluble proteins that allowed further studies. As indicated by shifts in the denaturation temperature of the protein encoded by LIC10791 (UniProt: Q72U71) in the presence of cAMP, cAMP is capable of binding to and stabilizing the protein, but cIMP does not affect protein stability. The melting temperature of protein Q72U71 in the absence of ligand was $52.9 \pm 0.4 ^\circ C$. Addition of cIMP gave at most only a slight shift in the melting temperature with a $T_{\text{m}}$ of $53.0 \pm 0.6 ^\circ C$ whereas in the presence of cAMP the denaturation temperature of protein Q72U71 was shifted to $62.9 \pm 0.7 ^\circ C$. In contrast, the protein encoded by LIC10237 (UniProt: Q72VQ9) did not show a significant shift in denaturation temperature in the presence of either cAMP or cIMP. When protein Q72U71 was analyzed by isothermal titration calorimetry, an association equilibrium constant of $6.1 \times 10^5$ M was observed for cAMP (Supporting Information Figure S2). In contrast, when titrated with cIMP, no binding isotherm was observed. Titration of protein Q72VQ9 with either cAMP or cIMP produced no binding isotherms indicating that the protein bound neither ligand.

**Implications of cIMP.** Conversion of cAMP to cIMP essentially inactivates the cyclic nucleotide as an *E. coli* signaling molecule and cIMP competes extremely weakly with cAMP for CRP binding (Figures 4 and 5). Indeed, given the numerous contacts between the ligand and protein in the crystal structures of the *E. coli* cAMP$\cdot$CRP complex, it is surprising that CRP binds cIMP so weakly since both salt bridges and eight out of ten hydrogen bonds of the cAMP$\cdot$CRP complex should be retained in the cIMP$\cdot$CRP complex. It seems likely that the intersubunit hydrogen bonds formed between the adenosine amino group and the hydroxyl groups of Thr127 and Serl28 play a role in facilitating the other ligand$\cdot$CRP interactions. The lack of DNA binding of the cIMP$\cdot$CRP is readily explained by the fact that the cAMP amino group hydrogen bonds to Thr127 and Serl28, which are involved in a coil-to-
helix transition that converts CRP into its DNA binding state. Indeed, although CRP binds cGMP more strongly than cIMP, the guanine base cannot make the key contacts with Thr-127 and Ser-128, and hence, as does the cIMP–CRP complex, the cGMP–CRP complex remains in a conformation that precludes DNA-binding. The conversion of cAMP to cIMP suggests the possibility that L. interrogans uses cIMP as a signaling molecule. As a preliminary test of this possibility, the genes encoding four CRP homologues were expressed, two of which gave soluble proteins amenable to further analysis. One of these proteins bound cAMP, but not cIMP, whereas the other protein bound neither nucleotide. Note that the L. interrogans genome encodes 18 putative adenylyl cyclases, the most of any known bacterial pathogen. This plethora of putative cAMP producing enzymes suggests an important function for cAMP in this bacterium. In a microarray study that assayed transcriptional regulation of genes upon shift from low osmolality to a higher osmolality increased transcription of locus LIC12327, which encodes a putative adenylate cyclase was observed. Such an osmotic shift has been associated with triggering of L. interrogans pathogenicity. Note that CadD may not be the only hydrolytic enzyme that L. interrogans has to manipulate cAMP levels. Locus LIC11606 encodes a protein that has all the conserved residues typical of bacterial phosphodiesterases. However, we were unable to detect phosphodiesterase activity with cAMP, cGMP, cIMP, or cCMP as substrates by NMR spectroscopy.

**METHODS**

**Materials.** All chemicals were purchased from Sigma-Aldrich except purine riboside-3′,5′-cyclic monophosphate (cPUMP, Figure 2), which was purchased from Axxora. The PCR primers used are given in Supporting Information, Table 1S.

**Cloning of LIC10459 from Leptospira interrogans.** The gene having locus tag LIC10459 encoding Uniprot protein Q72V44 was cloned from Leptospira interrogans serovar Copenhageni str. Fiocruz L1-130 genomic DNA from the ATCC. Restriction sites for NdeI (overlapping the initiation codon) and HindIII (downstream of the termination codon) were inserted into the forward and reverse primers, respectively. The PCR product was purified with a PCR cleanup system (QIagen), digested with NdeI and HindIII and ligated into vector pET30a(+), which had been previously digested with NdeI and HindIII. The LIC10459 termination codon was removed from the 3′-end to produce a C-terminal hexahistidine-tagged version of Uniprot protein Q72V44 that we have named CadD. The fidelity of gene amplification was confirmed by sequencing. The coding sequence of the pET30a construct was ligated into pSRK-Gm, a moderate copy number broad-host-range expression plasmid in which it was expressed from an intact tacZIAT promoter under stringent IPTG inducible control. The plasmid used to express and purify CRP and the CadD and fadH transcriptional reporter strains were described previously.

For expression and purification of CadD, the CadD-pET30a(+) construct was transformed into BL21(DE3) competent cells. A single colony was used to inoculate a 5 mL overnight culture of LB medium containing 50 μg/mL kanamycin. Each overnight culture was used to inoculate 1 L of LB medium containing 50 μg/mL kanamycin, and the cultures were grown at 37 °C and when an OD600 of 0.6 was reached were supplemented with 1.0 mM ZnCl2 and 50 μM isopropyl β-thiogalactopyranoside. At the time of induction, the temperature was lowered to 20 °C and shaken for 18 h prior to harvesting of the cells by centrifugation. The cells were resuspended in 20 mM potassium (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)) buffer (pH 7.5) containing 20 mM imidazole, 120 mM ammonium sulfate, 0.1 mg/mL phenylmethylsulfonyl fluoride, and 0.5 mg/mL bovine pancreatic deoxyribonuclease I and then lysed by sonication. The soluble protein fraction resulting from centrifugation to remove cellular debris was loaded onto a HisTrap column (GE Healthcare) and eluted with a gradient of imidazole.

**CadD Activity Screen.** CadD (1 μM) was screened for deaminase activity in 20 mM potassium HEPES (pH 7.5) against a library of compounds by UV–vis spectrometry. The compounds screened included adenosine, 2′-deoxyadenosine, 3′-deoxyadenosine, 2,5′-deoxyadenosine, 5′-deoxyadenosine, 3′,5′-cyclic AMP, ADP, ATP, N6-methyl-2′-deoxyadenosine, zeatin riboside, 7-deazadenosine, 8-oxoadenosine, S-adenosyl-homocysteine, S-adenosyl-methionine, adenosine, N-butyladenine, 6-methoxyurine, isoguanosine, benzyladenine, 2-chloroadenosine, 1-(6-amin-9H-purin-9-yl)-1-deoxy-N-ethyl-β-D-ribofuranonamidine, 4-(4-nitrophenyl)-3-phenyl-PI-pyrazol-5-ol, N,N-dimethyladenine, 2-chloroadenosine, N6-methyladenine, 2,6-dimethyl-adenosine, N6-ethenoadenosine, 6-chloropurine, 6-methylpurine, 8-oxoadenosine, 2,6-diaminopurine, 6-methylthiopurine, 6-mercaptopurine, cytosine, N6-methylguanine, 7-methylguanine, 6-deoxyaminofuranosine, pyromycin, pterin, 5-methyldeoxyctydine, cytidine, 2′-deoxyctydine, 2,4-diaminopyrididine, 4,6-diaminopyrimidine, thymopyrimidine, 4-aminopyrimidine, 2′-deoxyguanosine, 5′-methylthioadenosine, 5′-carboxylic acid adenosine, guanine, isoguanine, acetyl adenine, 2′-deoxy-3′-diphosphoadenosine, 2′-deoxy-5′-AMP, 2′-AMP, 2′-d AMP, 3′-AMP, 2′,3′-diphosphoadenosine, 3′,5′-diphosphoadenosine, acetyl-AMP, and cyclic-2′,3′-AMP. The substrate concentration was 80 μM in each case. Enzymatic activity was monitored through changes in absorbance between 240 and 300 nm on a SPECTRAmax Plus spectrophotometer (Molecular Devices).

**Production of cIMP from CAMP by CadD.** CadD was incubated with cyclic-3′,5′-AMP until the reaction was complete as confirmed by changes in the UV absorbance. Standards of cIMP and cAMP were loaded onto a C18 column in 20 mM ammonium acetate (pH 6.0) containing 5% buffer B. Compounds were eluted with a gradient of buffer B (20 mM ammonium acetate, pH 6.0, in 80% acetonitrile). After the standards had been run, the product of the CadD reaction with CAMP and was run followed by a run with cIMP alone. Samples of peak fractions detected by UV absorbance were dried and analyzed by ESI mass spectrometry. The CAMP peak fractions had an observed m/z of 328.022 for the M+H ion (theoretical m/z of 328.045 for C10H16N6O5P). The CIMP peak fractions had an observed m/z of 329.053 for the M+H ion (theoretical m/z of 329.029 for C10H16N5O4P).

**Expression of L. interrogans Cyclic-Nucleotide Binding Proteins.** The E. coli and M. tuberculosis CRPs, locus tags b3357 and Rsx3676, respectively, were used to search the genome of Leptospira interrogans for CAMP-binding proteins. The search revealed 10 proteins having more than 20% sequence identity to the characterized CRPs. The LIC10791, LIC10268, LIC11484, and LIC10237 loci were chosen for cloning because the encoded proteins had the highest sequence similarities.25,30 Identical residues with the known CRP proteins.

The L. interrogans genes with locus tags LIC10459, LIC10791, LIC10268, LIC11484, encoding putative cyclic nucleotide binding proteins were PCR amplified from L. interrogans genomic DNA, as described above. The PCR products were purified, digested with NcoI and HindIII, and ligated into vector pET30a(+) digested with the same restriction enzymes. The proteins encoded by these constructs were obtained as described above for CadD. Only two of the constructs (those of LIC10237 and LIC10791) gave soluble proteins, C-terminal hexahistidine tagged versions of UniProt proteins Q72U71 and Q72VQ9, respectively.

**Measurement of Kinetic Constants.** Assays were conducted with substrate concentrations of 3–200 μM. Deamination of CAMP was monitored by following the decrease in absorbance at 269 nm. Changes in extinction coefficients were calculated by subtracting the extinction coefficient of the product from the extinction coefficient of the substrate (ΔεS = 3430 M⁻¹ cm⁻¹). Assays were performed in 25 mM potassium HEPES (pH 7.5) at 30 °C. Inhibition of CAMP deaminase activity by cPUMP was determined by addition of 25 mM
CdD to 180 μM cAMP and concentrations of cPuMP ranging from 4 to 152 μM.

**Fluorescence Monitoring of Thermal Denaturation.** Proteins Q72U71 and Q72VQ9 were tested for binding of cAMP and cIMP by monitoring fluorescence in the presence of Sypro Orange (Invitrogen), which is supplied as a 5000x concentrated solution in DMSO. In a 50 μL assay 10 μM protein, 200 μM ligand, 25 mM potassium HEPES (pH 7.5), 10X Sypro Orange, and 10% DMSO were combined and relative fluorescence units were monitored. Ten duplicate reactions were run simultaneously.

**Isothermal Titration Calorimetry.** Proteins Q72U71 (36 μM) and Q72VQ9 (50 μM) were titrated with cAMP (0.25 mM) or cIMP (1 mM) to determine the association equilibrium constants.

**Metal Analysis.** The metal content of the proteins was determined by ICP-MS. Protein samples for ICP-MS were digested with HNO₃ by refluxing for ~45 min to prevent protein precipitation during the measurement. The protein concentration was adjusted to ~1.0 μM with 1% (v/v) HNO₃.

**Data Analysis.** Steady state kinetic data were analyzed using Softmax Pro, version 5.4. Kinetic parameters were determined by fitting the data to eq 1 using the nonlinear least-squares fitting program in SigmaPlot 9.0. In this equation, A is the substrate concentration, kₘ is the Michaelis constant, v is the velocity of the reaction, and kₐ is the turnover number. The inhibition constant for cPuMP was determined by fitting the plot of residual enzyme activity against inhibitor concentration to eq 2. In this equation, vᵢ is the residual enzyme activity in the presence of cPuMP, vₙ is the enzyme activity in the absence of inhibitor, and I is the inhibitor concentration.

\[
\frac{v}{v_i} = k_{cat}A/(K_m + A)
\]

\[
\frac{v}{v_n} = A/(K_m(1 + [I]/K_i + A))
\]

**Electrophoretic Mobility Shift Assays.** Binding of cAMP—CRP to the fadD promoter CRP binding site was measured essentially as previously reported with minor modifications. The digoxigenin-labeled fadD probe (0.2 pmol) was incubated with CRP protein purified as previously described in the presence or absence of cyclic nucleotide for 20 min at RT and then analyzed by electrophoresis on native 7.5% polyacrylamide gels PAGE. To test the effects of CdD on binding of fadD promoter cAMP—CRP complex various amounts of enzyme was added to the gel shift incubations.

**Bacterial Media and Growth Conditions.** The medium for carbon source utilization was M9 salts containing 0.4% carbohydrate. The medium for CAMP determinations and gene expression assays by β-galactosidase activity (assayed as previously described) was RB medium (10% tryptone and 1% yeast extract) because growth on the other two times in minimal medium (10% tryptone and 1% yeast extract) because growth on amino acids results in high levels of cAMP. The boiled supernatants were centrifuged (12 000 g) and then placed in a boiling water bath for 20 min for release of cAMP. The boiled supernatants were centrifuged (12 000 g) and then placed in a boiling water bath for 20 min for release of cAMP. The boiled supernatants were centrifuged (12 000 g) and then placed in a boiling water bath for 20 min for release of cAMP.

**Determination of cAMP Levels.** The CAMP Direct Enzyme Immunoassay kit (Sigma) was used to assay the cAMP levels in midlog phase bacterial cultures in RB medium. The bacterial cultures were adjusted to an absorbance at 600 nm of 1.0 and 1 mL of cell suspension was washed three times (once in the same medium, and the other two times in minimal medium M9) by centrifugation and resuspension. The air-dried bacterial pellets were dissolved in 300 μL of 0.1 M HCl to block endogenous phosphodiesterase activity and then placed in a boiling water bath for 20 min for release of cAMP. The boiled supernatants were centrifuged (12 000 g, 20 min) and assayed. A series of dilutions of a CAMP standard to give 200, 50, 12.5, 3.12, or 0.78 pmol/mL were used to obtain a standard curve. The assay protocol recommended by the manufacturer for the bacterial and cAMP standards was followed, and absorbance of each microtiter plate well was read at 405 nm. The net absorbance bound for each well was calculated by subtracting the non-specific binding of wells lacking cAMP from the experimental samples. A standard curve was plotted and the cAMP levels of the bacterial samples were determined by interpolation.

**ASSOCIATED CONTENT**

**Supporting Information**

Oligonucleotides used in this work and isothermal titration calorimetry data. This material is available free of charge via the Internet at http://pubs.acs.org.

**AUTHOR INFORMATION**

*Corresponding Author*

E-mail: j-cronan@life.uiuc.edu.

**Author Contributions**

A.M.G. and Y.F. contributed equally to this work.

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

This research was supported by a grant from the Robert A Welch foundation (A-840) and by a cooperative agreement from the National Institute of General Medical Sciences (U54GM093342). We thank R. Kumar for valuable discussions.

**REFERENCES**


